Article
T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
Molecular cancer therapeutics - 1 Nov 2017
Watanabe Satomi, Yoshida Takeshi, Kawakami Hisato, Takegawa Naoki, Tanizaki Junko, Hayashi Hidetoshi, Takeda Masayuki, Yonesaka Kimio, Tsurutani Junji, Nakagawa Kazuhiko
Abstract excerpt
T790M mutation-selective EGFR tyrosine kinase inhibitors (EGFR-TKI) have demonstrated clinical benefits in non-small cell lung cancer (NSCLC) patients harboring T790M mutation, which is the major cause of resistance to EGFR-TKI. However, their efficacy is limited, possibly due to the emergence of apoptosis resistance in T790M-positive NSCLC. We previously identified Src family kinases as cooncogenic drivers along...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.